% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Knippertz:128915,
author = {I. Knippertz and A. Deinzer and J. Dörrie and N. Schaft
and D. M. Nettelbeck$^*$ and A. Steinkasserer},
title = {{T}ranscriptional {T}argeting of {M}ature {D}endritic
{C}ells with {A}denoviral {V}ectors via a {M}odular
{P}romoter {S}ystem for {A}ntigen {E}xpression and
{F}unctional {M}anipulation.},
journal = {Journal of Immunology Research},
volume = {2016},
issn = {2314-7156},
address = {New York, NY},
publisher = {Hindawi},
reportid = {DKFZ-2017-04928},
pages = {1 - 17},
year = {2016},
abstract = {To specifically target dendritic cells (DCs) to
simultaneously express different therapeutic transgenes for
inducing immune responses against tumors, we used a combined
promoter system of adenoviral vectors. We selected a
216 bp short Hsp70B' core promoter induced by a mutated,
constitutively active heat shock factor (mHSF) 1 to drive
strong gene expression of therapeutic transgenes MelanA,
BclxL, and IL-12p70 in HeLa cells, as well as in mature DCs
(mDCs). As this involves overexpressing mHSF1, we first
evaluated the resulting effects on DCs regarding
upregulation of heat shock proteins and maturation markers,
toxicity, cytokine profile, and capacity to induce
antigen-specific CD8(+) T cells. Second, we generated the
two-vector-based 'modular promoter' system, where one vector
contains the mHSF1 under the control of the human CD83
promoter, which is specifically active only in DCs and after
maturation. mHSF1, in turn, activates the Hsp70B' core
promotor-driven expression of transgenes MelanA and IL-12p70
in the DC-like cell line XS52 and in human mature and hence
immunogenic DCs, but not in tolerogenic immature DCs. These
in vitro experiments provide the basis for an in vivo
targeting of mature DCs for the expression of multiple
transgenes. Therefore, this modular promoter system
represents a promising tool for future DC-based
immunotherapies in vivo.},
keywords = {Antigens, CD (NLM Chemicals) / BCL2L1 protein, human (NLM
Chemicals) / CD83 antigen (NLM Chemicals) / Cytokines (NLM
Chemicals) / DNA-Binding Proteins (NLM Chemicals) /
Immunoglobulins (NLM Chemicals) / MART-1 Antigen (NLM
Chemicals) / Membrane Glycoproteins (NLM Chemicals) /
Transcription Factors (NLM Chemicals) / bcl-X Protein (NLM
Chemicals) / heat shock transcription factor (NLM Chemicals)
/ Interleukin-12 (NLM Chemicals)},
cin = {F110},
ddc = {610},
cid = {I:(DE-He78)F110-20160331},
pnm = {316 - Infections and cancer (POF3-316)},
pid = {G:(DE-HGF)POF3-316},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:27446966},
pmc = {pmc:PMC4942663},
doi = {10.1155/2016/6078473},
url = {https://inrepo02.dkfz.de/record/128915},
}